Instructions for Longidaza lyophilisate (Bovhyaluronidase azoximer) solution for injection 5 ampoules
English product name
Longidaza®
Form of release
lyophilisate d / prigot. r-ra d / injection 1500 IU : fl. 5 pcs.
lyophilisate d / prigot. r-ra d / injection 3000 IU: fl. 5 pcs.
Description:
Lyophilisate for the preparation of a solution for injection in the form of a porous mass of white or white color with a yellowish or brownish tint, hygroscopic.
1 fl.
bovgialuronidase azoximer (longidase®) 3000 IU
Excipients: mannitol- up to 20 mg.
20 mg - vials of dark glass 1 hydrolytic class with capacity
ATC codes
V03AX Other Medicines
Clinical and pharmacological groups / Group affiliation
Enzyme preparation
Active ingredient
bovialuronidase azoximer
Pharmaco-therapeutic group
Enzyme agent
Storage conditions
The drug should be stored out of the reach of children at a temperature of 2 ° to 8 ° C.
Shelf life
Shelf life - 2 years. Do not use after expiration date.
Drugs:
Bovgialuronidase azoximer is a conjugate of the proteolytic enzyme hyaluronidase with a high-molecular carrier from the group of derivatives of N-oxide poly-1,4-ethylenepiperazine. Bovgialuronidase azoximer has the entire spectrum of pharmacological properties inherent in drugs with hyaluronidase activity.
Testimony:
The drug is prescribed to adults as part of complex therapy for the treatment and prevention of diseases accompanied by connective tissue hyperplasia.
In gynecology:
treatment and prevention of adhesions in the pelvis with inflammatory diseases of the internal genital organs, incl. tubal-peritoneal infertility, intrauterine synechia, chronic endometritis.
In urology:
treatment of chronic prostatitis;
treatment of interstitial cystitis.
In surgery:
treatment and prevention of adhesions after surgical interventions on the abdominal organs;
long-term non-healing wounds.
In dermatovenereology and cosmetology:
treatment of limited scleroderma;
Treatment of non-infectious onichodstrophy;
Treatment of keloid, hypertrophic scars after pyoderma, injuries, burns, surgeries;
Treatment of vulgar acne II-IV stage with scar deformities (postacne).
In pulmonology and phthisiology:
Treatment of pneumosclerosis, fibrotic alveolitis
treatment of tuberculosis (cavernous-fibrotic, infiltrative, tuberculosis).
In rheumatology:
treatment of joint contracture (including Dupuytren contracture and flexor tendogenic brush contracture), arthrosis, ankylosing spondyloarthritis, hematoma.
To increase bioavailability:
Combined administration of antibacterial drugs in urology, gynecology, surgery, dermatovenereology, pulmonology, to strengthen the local anesthetics.
Method of use, course and dosage:
Longidaza® is applied n/c, v/m, externally.
The methods of use are chosen by the doctor depending on the diagnosis, severity and clinical course of the disease.
Preparation of solution
The contents of the vial of Longidaza® 3000 ME are dissolved in 1.0-2.0 ml 0.5% of the solution of procaine (novocaine) for injection. In the case of procaine (novocaine) intolerance, Longidase® is dissolved in the same volume of 0.9% sodium solution for injection or water for injection.
The contents of the vial of Longidaza® 1500 ME are dissolved in 1.0-2.0 ml 0.5% of the solution of procaine (novocaine) for injection. In the case of procaine (novocaine) intolerance, Longidaza® is dissolved in the same volume of 0.9% sodium solution for injection or water for injection.
For the p/k or v/m administration of Longidaza® in a dose of 4500 ME, the contents of the vial of Longidaza® 3000 ME are dissolved in 1.0-2.0 ml 0.5% of the solution of procaine (novocaine), and the contents of the vial of Longidaza® 1500 ME are dissolved in 1.0-2.0 ml 0.5% of the solution of procaine (novocaine). The two solutions produced are alternately recruited into a syringe with a volume of at least one.
When the contents of the vial of Longidaza® 3000 ME are diluted in 0.5 ml of distilled water, dissolved for 3-4 minutes and applied 1 drop (about 300 ME of Longidaza® preparation) to the distal phalanges of the fingers with the aid of photophoresis for treating onichodstrophy.
For photophoresis or ultrathonophoresis in the treatment of vulgar acne, 1 vial of Longidaza® 3000 ME is diluted in 2-5 ml ultrasound gel (Mediagel-T) and applied to the lesion site.
For the introduction of the preparation with the aid of ultrasound in the treatment of contracture, the contents of the vial with Longidaza 3000 ME are dissolved in 1.0 ml of saline solution, mixed with 5-7 g of vaseline and applied to the rumen area.
The contents of the vial of Longidaza® 3000 ME are dissolved in 2.0 ml and at a dosage of 1500 ME when used to increase bioavailability
Use in children
The drug is contraindicated at the age of 18.
- Nosology (ICD codes)
- A15
- Respiratory tuberculosis confirmed bacteriologically and histologically
- J84.1
- Other interstitial lung diseases with mention of fibrosis
- K66.0
- Abdomen
- L60.3
- Nail dystrophy
- L70.0
- Common eels [acne vulgaris]
- L91.0
- Hypertrophic scar
- L91.8
- Other hypertrophic skin changes
- L94.0
- Localized scleroderma [morphea]
- M15
- Polyarthrosis
- M24.5
- Joint contracture
- M45
- Ankylosing spondylitis
- M47
- Spondylosis
- M72.0
- Brass fascial fibromatosis [Dupuytren]
- N30
- Cystitis
- N41
- Inflammatory prostate diseases
- N71
- Inflammatory disease of the uterus, except the cervix (including endometritis, myometritis, metritol, pyometra, abscess of the uterus)
- N85.6
- Intrauterine synechiae
- N97
- Female infertility
- N99.4
- Small pelvic post-operative adhesions
- R23.4
- Changes in skin structure
- T14.0
- Superficial injury of an unspecified area of the body (including abrasion, bruising, bruising, hematoma, bite of a non-venomous insect)
- T14.1
- Open wound of unspecified body region
- Testimony
